Patent ID: 8945578
Filing Date: 2015-02-03
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for the treatment of cancer in a human leukocyte antigen (HLA)-A*3303 positive subject, comprising administering to the subject an isolated peptide comprising Thr Ser Glu Lys Pro Phe Ser Cys Arg (SEQ ID NO: 5), wherein the peptide binds to an HLA-A*3303 molecule and induces a Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte (CTLs) in the subject, wherein the cancer is selected from leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer, and wherein the peptide is administered via a route selected from the group consisting of intradermal, subcutaneous, intramuscular, intravenous, nasal and oral.